Akebia Presents Positive Vadadustat Phase 2 Dialysis Data at American Society of Nephrology Kidney Week 2015 Annual Meeting

Akebia Therapeutics, Inc. 

announced that Phase 2 results for vadadustat in dialysis patients with anemia related to chronic kidney disease (CKD) were presented in a late-breaker poster presentation at the American Society of Nephrology (ASN) Kidney Week 2015 annual meeting, which is being held in San Diego, California from November 3-8, 2015.  Dr. Volker H. Haase, Professor of Medicine, Division of Nephrology and Hypertension at Vanderbilt University Medical Center, was the first author of the presentation which is available online at www.akebia.com/media/publications. The Phase 2 study achieved its primary endpoints of maintaining stable hemoglobin levels over 16 weeks of treatment in all three cohorts of patients converting from recombinant erythropoiesis-stimulating agents (rESA) to vadadustat, as shown in the chart below ("Mean Hemoglobin Levels Over Time by Dose Cohort") and in the poster available online. In addition, the study also demonstrated sustained improvements in iron mobilization